Abcellera Biologics Inc

NASDAQ:ABCLUnited States

AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.

Contact Information

Headquarters

2215 Yukon StreetVANCOUVER, BC, Canada V5Y 0A1

Phone

604-559-9005

Fax

---

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Carl Hansen

Co-Founder, Chief Operating Officer, Director

Veronique Lecault

Chief Financial Officer

Andrew Booth

Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer

Tryn Stimart

Independent Director

Michael Hayden